UTv Videos

Alicia Morgans, MD, MPH, shares findings from a real-world study assessing darolutamide or abiraterone in combination with ADT plus docetaxel for mHSPC.

At 1 year, patients randomized to Rezūm showed a 4.6-point greater improvement on the IPSS symptom score compared with those escalated to combination therapy.

On actionable guidance for community practitioners, Kamat's most emphatic recommendation is early pathology review.

Antoni Vilaseca Cabo, MD, characterizes these results as proof of concept for the local delivery approach, with phase 2 and 3 trials now underway.

Guerrero-Ramos argues that landmark survival data from recent trials justify perioperative immunotherapy in muscle-invasive bladder cancer, while acknowledging that validated tools for individual patient selection remain elusive and that urologists must engage closely with medical oncology to deliver optimal care.

On diagnostic pitfalls, Necchi highlights penile cancer as a particularly common source of delay.

On counseling patients who want to avoid cystectomy, Bogdana Schmidt, MD, MPH, points to trimodality therapy as the established bladder-preserving option, supported by longer-term data and propensity-matched analyses showing outcomes comparable to cystectomy in selected patients.

Daniel J. George, MD, discusses results from a survey examining the experiences and unmet needs of caregivers supporting patients with metastatic prostate cancer.

Sam S. Chang, MD, MBA, highlights 2 studies presented at the 2026 ASCO Genitourinary Cancers Symposium in San Francisco, California, that he believes are particularly impactful for clinicians treating bladder cancer.

Mustafa J. Saleh, MD, highlights new research exploring whether germline-based polygenic risk scores could help predict outcomes for patients with kidney cancer.

On Hugo's modular arm architecture, Porter contrasts it with the traditional "boom" design that has dominated robotic surgery for over 2 decades.

Maha H. A. Hussain, MD, FASCO, FACP, outlines the design and key findings from a phase 2 trial of abiraterone plus olaparib vs each agent alone in mCRPC.

Telemedicine has also expanded access, allowing patients to choose either virtual or in-person visits. However, Kaylani Narra, MD, emphasized that limited genetic counseling capacity remains a major barrier.

According to Sophia Kamran, MD, innovation in bladder cancer is expanding treatment options and patient-centered care.

Vignesh T. Packiam, MD, reviews several bladder cancer studies from ASCO GU 2026 that he described as clinically meaningful for practicing urologists.

Rubenstein emphasizes the importance of strong clinical documentation and preparation by billing teams.

Laura Bukavina, MD, MPH, MSc, sat down to discuss the emerging role of ctDNA in guiding treatment decisions for patients with muscle-invasive bladder cancer, drawing on findings from the RETAIN and RETAIN 2 trials.

For asymptomatic renal stones, Mathew D. Sorensen, MD, MS, FACS, said he believes Break Wave could meaningfully influence the long-standing debate between surveillance and early intervention.

Chad Tang, MD, discusses the development of a prognostic model—K-COMPASS—for patients with oligometastatic clear cell renal cell carcinoma.

Robert S. Svatek, MD, discusses the background and key findings from the SWOG S1602 trial, evaluating BCG strain differences and intradermal BCG before intravesical therapy for patients with BCG-naïve NMIBC.

Sophia C. Kamran, MD, highlights some of the key bladder cancer trials presented at ASCO GU 2026 from the perspective of a radiation oncologist.

According to Alex Tatem, MD, misinformation online and aggressive marketing frequently push patients toward unregulated providers offering injectable silicone or other non-medical substances.

A permanent J code helps standardize billing and clarifies expected payment levels, often embedding reimbursement terms into payer contracts.

Matthew D. Galsky, MD, discusses what is needed for successful integration of BCG/ICI combinations in BCG-naive non–muscle invasive bladder cancer.

Kristen R. Scarpato, MD, MPH, discusses the potential role of emerging immunotherapy-based combinations in the treatment of BCG-naive, high-risk non–muscle invasive bladder cancer.

As immunotherapy and antibody-drug conjugates move earlier in treatment, questions about sequencing therapies are emerging.

Toni K. Choueiri, MD, discusses the background and key findings from the phase 3 LITESPARK-022 trial.

David R. Wise, MD, PhD, highlights initial findings from a phase 1b study of pasritamig plus docetaxel in patients with metastatic castration-resistant prostate cancer.